Oncolytics (ONCY) Biotech announced that the common shares in the capital of the company will be voluntarily delisted from the Toronto Stock Exchange at the close of markets on August 22, 2025, pursuant to the company’s application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will not affect the company’s listing on the Nasdaq. After delisting from the TSX, the shares will continue to trade on the Nasdaq under the symbol “ONCY.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech to Hold Virtual Annual Meeting and Announce Q2 Financial Results
- ONCY Upcoming Earnings Report: What to Expect?
- Buy Rating on Oncolytics Biotech: Strategic Focus on Pancreatic Cancer and Undervalued Stock Potential
- Oncolytics Biotech Engages FDA for Pivotal Pancreatic Cancer Study
- Oncolytics engaging FDA for registration-enabled pancreatic cancer trial